10 November 2020
Dechra Veterinary Products has unveiled a new apple flavoured presentation of Equipalazone, its trusted powerful pain relief product.
Equipalazone, an oral powder that can be used to treat a variety of musculoskeletal disorders in horses and ponies, now comes with apple flavouring as standard with the existing unflavoured option rebranded and still available as Equipalazone Original.
Equipalazone contains phenylbutazone, the analgesic, non-steroidal antiinflammatory drug (NSAID). It is most commonly used by vets to treat lameness in equines and can be prescribed as a treatment for osteoarthritic conditions, acute and chronic laminitis, bursitis and carpitis as well as to reduce post-surgical soft tissue reaction.
The new apple flavoured Equipalazone retains Dechra’s unique Microcaps® technology and remains the only phenylbutazone powder on the market with no added sugar.
It is available to dispense in compact 1.5g sachets that are added to feed, giving vets a convenient and simple option for dispensing in practice or in the field.
Dechra Brand Manager Emma Jennings said: “The new apple flavoured Equipalazone is the same tried and trusted popular product that vets have been using for many years but the enhanced apple flavour should improve compliance amongst even the fussiest of feeders.
Equipalazone has been a best-selling treatment delivering powerful pain relief since we brought it to the market as the first microencapsulated phenylbutazone more than 45 years ago. The new apple flavoured presentation will give vets even more choice when it comes to providing pain relief and anti-inflammatory treatment for equine conditions.”
For more information visit www.dechra.co.uk.
Equipalazone® - a new generation of powerful equine pain relief